Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study

BACKGROUND: Adjuvant tamoxifen therapy approximately halves the risk of estrogen receptor positive breast cancer recurrence, but many women do not respond to therapy. Observational studies nested in clinical trial populations suggest that overexpression or nuclear localization of p21-activated kinas...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Acta Oncol
Hlavní autoři: Ahern, Thomas P., Cronin-Fenton, Deirdre P., Lash, Timothy L., Sørensen, Henrik Toft, Ording, Anne Gulbech, Hamilton-Dutoit, Stephen J., Hellberg, Ylva
Médium: Artigo
Jazyk:Inglês
Vydáno: 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4943575/
https://ncbi.nlm.nih.gov/pubmed/27056567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/0284186X.2016.1150606
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky